Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up
This is a multicenter, randomized, controlled trial conducted at 31 French hospital. Patients with biopsy-proven PMN and nephrotic syndrome after 6 months of nonimmunosuppressive antiproteinuric treatment (NIAT) were randomly assigned to 6-month therapy with NIAT and 375 mg/m2 intravenous rituximab on days 1 and 8 (n=37) or NIAT alone (n=38). During the observational phase, remission rates before change of assigned treatment were 24 of 37 (64.9%) and 13 of 38 (34.2%) patients in NIAT-rituximab and NIAT groups, respectively (P<0.01). Positive effect of rituximab on proteinuria remission occurred after 6 months.
:
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis
Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis
Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit
Source: Nephrology Now - Category: Urology & Nephrology Authors: Nephrology Now editors Tags: Clinical Nephrology Clinical Trial Results Glomerulonephritis Source Type: research
More News: Clinical Trials | Glomerulonephritis | Hospitals | Intensive Care | Nephrotic Syndrome | Proteinuria | Rituxan | Urology & Nephrology | Vasculitis